These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32433892)

  • 1. Predictive model of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension.
    Yorifuji K; Uemura Y; Horibata S; Tsuji G; Suzuki Y; Nakayama K; Hatae T; Kumagai S; Emoto N
    Can J Physiol Pharmacol; 2020 Sep; 98(9):625-628. PubMed ID: 32433892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHST3 and CHST13 polymorphisms as predictors of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension.
    Yorifuji K; Uemura Y; Horibata S; Tsuji G; Suzuki Y; Miyagawa K; Nakayama K; Hirata KI; Kumagai S; Emoto N
    Pharmacol Res; 2018 Sep; 135():259-264. PubMed ID: 30118797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
    Zhao Q; Guo N; Chen J; Parks D; Tian Z
    J Clin Pharm Ther; 2022 Feb; 47(2):146-156. PubMed ID: 34319626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data.
    Dong S; Guo X; Wang H; Sun C
    Ther Adv Respir Dis; 2024; 18():17534666231223606. PubMed ID: 38179676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports.
    Ito T; Ozaki Y; Son Y; Nishizawa T; Amuro H; Tanaka A; Tamaki T; Nomura S
    J Med Case Rep; 2014 Jul; 8():250. PubMed ID: 25015229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of novel bosentan analogues as endothelin receptor antagonists for pulmonary arterial hypertension.
    Panchal J; Jaiswal S; Jain S; Kumawat J; Sharma A; Jain P; Jain S; Verma K; Dwivedi J; Sharma S
    Eur J Med Chem; 2023 Nov; 259():115681. PubMed ID: 37515921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
    Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
    Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chondroitin sulfate mediates liver responses to injury induced by dual endothelin receptor inhibition.
    Ryanto GRT; Yorifuji K; Ikeda K; Emoto N
    Can J Physiol Pharmacol; 2020 Sep; 98(9):618-624. PubMed ID: 32315540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 polymorphisms in patients with bosentan-induced liver toxicity.
    Roustit M; Fonrose X; Montani D; Girerd B; Stanke-Labesque F; Gonnet N; Humbert M; Cracowski JL
    Clin Pharmacol Ther; 2014 Jun; 95(6):583-5. PubMed ID: 24842639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of CYP2C9*2 with bosentan-induced liver injury.
    Markova SM; De Marco T; Bendjilali N; Kobashigawa EA; Mefford J; Sodhi J; Le H; Zhang C; Halladay J; Rettie AE; Khojasteh C; McGlothlin D; Wu AH; Hsueh WC; Witte JS; Schwartz JB; Kroetz DL
    Clin Pharmacol Ther; 2013 Dec; 94(6):678-86. PubMed ID: 23863877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
    Petrovič M; Locatelli I
    Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
    Macías Saint-Gerons D; de la Fuente Honrubia C; Montero Corominas D; Catalá-López F
    Med Clin (Barc); 2014 Apr; 142(8):333-42. PubMed ID: 23540381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
    Martynyuk TV; Aleevskaya AM
    Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.
    Aypar E; Alehan D; Karagöz T; Aykan H; Ertugrul İ
    Cardiol Young; 2020 May; 30(5):681-685. PubMed ID: 32290885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension.
    Hiramoto Y; Shioyama W; Kuroda T; Masaki M; Sugiyama S; Okamoto K; Hirota H; Fujio Y; Hori M; Yamauchi-Takihara K
    Circ J; 2007 Mar; 71(3):367-9. PubMed ID: 17322637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
    Aversa M; Porter S; Granton J
    Drug Saf; 2015 May; 38(5):419-35. PubMed ID: 25792028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension.
    Seyfarth HJ; Favreau N; Tennert C; Ruffert C; Halank M; Wirtz H; Mössner J; Rosendahl J; Kovacs P; Wittenburg H
    Ann Hepatol; 2014; 13(6):803-9. PubMed ID: 25332267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiopulmonary exercise testing to evaluate the exercise capacity of patients with inoperable chronic thromboembolic pulmonary hypertension: an endothelin receptor antagonist improves the peak PETCO2.
    Hirashiki A; Adachi S; Nakano Y; Kono Y; Shimazu S; Shimizu S; Morimoto R; Okumura T; Takeshita K; Yamada S; Murohara T; Kondo T
    Life Sci; 2014 Nov; 118(2):397-403. PubMed ID: 24641953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum to "CHST3 and CHST13 polymorphisms as predictors of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension" [Pharmacol. Res. 135 (2018) 259-264].
    Yorifuji K; Uemura Y; Horibata S; Tsuji G; Suzuki Y; Miyagawa K; Nakayama K; Hirata KI; Kumagai S; Emoto N
    Pharmacol Res; 2019 Jan; 139():570. PubMed ID: 30292639
    [No Abstract]   [Full Text] [Related]  

  • 20. FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion.
    Berger RM; Haworth SG; Bonnet D; Dulac Y; Fraisse A; Galiè N; Ivy DD; Jaïs X; Miera O; Rosenzweig EB; Efficace M; Kusic-Pajic A; Beghetti M
    Int J Cardiol; 2016 Jan; 202():52-8. PubMed ID: 26386921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.